Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBA-0405 Phase 0 Microdosing in Solid Tumors
NCT06273852Phase 1Completed
- Sponsor
- Pure Biologics
- Start
- Apr 2024
- Primary completion
- Mar 2025
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PBA-0405 in head and neck squamous cell carcinoma (HNSCC), soft tissue sarcoma (STS) and triple-negative breast cancer (TNBC), sponsored by Pure Biologics. Primary endpoint: Quantification of Cell Death and Immune Cell Biomarkers by immuno-histochemistry (IHC) and In-Situ Hybridization (ISH). Started Apr 2024; status: completed.
02
Drugs
PBA-0405
03
Conditions
head and neck squamous cell carcinoma (HNSCC)soft tissue sarcoma (STS)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06273852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06273852.